Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: Treatment efficacy and toxicity in U87 and C6 intracranial gliomas Academic Article uri icon

Overview

MeSH Major

  • Brain Neoplasms
  • Corticotropin-Releasing Hormone
  • Dacarbazine
  • Dexamethasone
  • Glioma

abstract

  • hCRF was more effective than either dexamethasone or temozolomide in the treatment of U87 xenografts, and results included improved prognosis with long-term survivors and only mild toxicity. The therapeutic efficacy of hCRF seems to be dependent on tumor hCRF receptor (CRFr) expression. These results support further clinical assessment of the therapeutic efficacy of hCRF and levels of CRFr expression in different human gliomas.

publication date

  • May 15, 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3131845

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-10-3203

PubMed ID

  • 21385926

Additional Document Info

start page

  • 3282

end page

  • 92

volume

  • 17

number

  • 10